SINO BIOPHARMACEUT HKD0.025 (SBMFF) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of SINO BIOPHARMACEUT HKD0.025 (NASDAQ:SBMFF) from a hold rating to a buy rating in a report released on Wednesday morning. They currently have $1.00 price objective on the stock.

According to Zacks, “Sino Biopharmaceutical Limited researches, develops, produces and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis. Sino Biopharmaceutical Limited is headquartered in Wanchai, Hong Kong. “

Shares of SINO BIOPHARMACEUT HKD0.025 (NASDAQ SBMFF) opened at 0.99 on Wednesday. The firm has a market capitalization of $7.34 billion and a PE ratio of 26.05. The firm’s 50-day moving average is $0.89 and its 200 day moving average is $0.82. SINO BIOPHARMACEUT HKD0.025 has a 52 week low of $0.63 and a 52 week high of $0.99.

COPYRIGHT VIOLATION NOTICE: “SINO BIOPHARMACEUT HKD0.025 (SBMFF) Stock Rating Upgraded by Zacks Investment Research” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/09/10/sino-biopharmaceut-hkd0-025-sbmff-stock-rating-upgraded-by-zacks-investment-research.html.

Get a free copy of the Zacks research report on SINO BIOPHARMACEUT HKD0.025 (SBMFF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SINO BIOPHARMACEUT HKD0.025 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SINO BIOPHARMACEUT HKD0.025 and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply